



Asymmetric bioreduction of activated alkenes to industrially relevant optically active compounds

Christoph K. Winkler^b, Gábor Tasnádi^{a,b}, Dorina Clay^b, Mélanie Hall^b, Kurt Faber^{b,*}

^a ACIB Co. c/o, Heinrichstrasse 28, 8010 Graz, Austria

^b Department of Chemistry, Organic & Bioorganic Chemistry, University of Graz, Heinrichstrasse 28, 8010 Graz, Austria

ARTICLE INFO

Article history:

Received 31 October 2011

Received in revised form 23 March 2012

Accepted 28 March 2012

Available online 4 April 2012

Keywords:

Asymmetric reduction

Biocatalysis

Ene-reductase

Old Yellow Enzyme

Chiral building blocks

ABSTRACT

Ene-reductases from the 'Old Yellow Enzyme' family of flavoproteins catalyze the asymmetric reduction of various α,β -unsaturated compounds at the expense of a nicotinamide cofactor. They have been applied to the synthesis of valuable enantiopure products, including chiral building blocks with broad industrial applications, terpenoids, amino acid derivatives and fragrances. The combination of these highly stereoselective biocatalysts with a cofactor recycling system has allowed the development of cost-effective methods for the generation of optically active molecules, which is strengthened by the availability of stereo-complementary enzyme homologues.

© 2012 Elsevier B.V. Open access under [CC BY-NC-ND license](http://creativecommons.org/licenses/by-nc-nd/3.0/).

1. Introduction

The increasing demand for small enantiopure molecules as chiral building blocks for the synthesis of biologically active compounds (most notably active pharmaceutical ingredients – API) has contributed to the development of highly specific synthetic strategies. The reduction of alkenes, for instance, is a powerful tool in modern asymmetric synthesis and various approaches are now available on industrial scale. Transition-metal based homogeneous catalysis has reached high standards (Knowles, 2002; Noyori, 2002), and related fields of catalysis are now becoming competitive in this area. Metal-free organocatalysis uses general acid-type catalysts to perform stereoselective transfer hydrogenation, but suffers from low atom economy due to the requirement for molar amounts of the 'Hantzsch ester' used as reductant (List and Yang, 2006; Yang et al., 2005). Nature, on the other hand, provides an attractive sustainable and cost-effective alternative. The biocatalytic analog relies on ene-reductases to perform the reduction of activated C=C bonds. These enzymes belong to the 'Old Yellow Enzyme' family of nicotinamide-dependent flavoproteins and have been intensely investigated over the past five years in view of their applicability in preparative-scale biotransformations (Hall et al., 2010; Stuermer et al., 2007; Toogood et al., 2010). They catalyze the highly

stereoselective reduction of a broad variety of α,β -unsaturated compounds, affording excellent yields and enantiomeric excess, while working under mild conditions of pH and temperature. A whole set of homologous enzymes has been developed and several industrially relevant molecules could be obtained in nonracemic form. This review focuses on this new enzyme platform, presenting pertinent examples while stressing on general rules that should help chemists incorporate ene-reductases in the design of asymmetric synthetic routes.

2. System

2.1. Reaction mechanism

The mechanism of the ene-reductase-catalyzed reduction of α,β -unsaturated compounds has been studied in great detail (Kohli and Massey, 1998). The reaction was shown to proceed via the stereoselective transfer of a hydride (derived from the reduced flavin-cofactor) onto C β , while a Tyr-residue adds a proton (ultimately derived from the solvent) onto C α from the opposite side (Fig. 1). The overall addition of [2H] onto a C=C bond resembles a Michael-type addition of a complex hydride and results with exclusive relative *trans*-stereospecificity.¹ Reduction of the

* Corresponding author. Tel.: +43 316 380 5332; fax: +43 316 380 9840.
E-mail address: Kurt.Faber@Uni-Graz.at (K. Faber).

¹ Rare cases for *cis*-addition were observed with plant cell cultures and flavin-independent reductases: Shimoda, K., Ito, D.I., Izumi, S., Hirata, T., 1996. Novel




Fig. 1. Asymmetric bioreduction of activated alkenes using ene-reductases.

oxidized flavin cofactor at the expense of NAD(P)H closes the catalytic cycle (Fig. 1). Ene-reductases often show relaxed specificities for NADH or NADPH as cofactor, which allows to choose the recycling system on a case-to-case basis. The enzymes have been shown to tolerate organic co-solvents very well, especially water immiscible ones, in up to 50%, v:v (Stueckler et al., 2010a; Yanto et al., 2011).

2.2. Substrates

Only C=C-bonds that are electronically activated by a conjugated electron-withdrawing group (EWG) are reduced, non-activated (isolated) alkenes are unreactive. The following functional groups may serve as 'activators':

- (i) α,β -Unsaturated carboxaldehydes (enals) are good substrates and yield the expected saturated aldehydes as products when pure ene-reductases are used (Stueckler et al., 2010a). However, in whole-cell biotransformations (using e.g. baker's yeast), carbonyl reduction is a dominant side reaction forming saturated *prim*-alcohols via over-reduction of the product or allylic alcohols by depleting the substrate (Hall et al., 2006; Mueller et al., 2006).
- (ii) α,β -Enones are usually well accepted, competing carbonyl reduction is less dominant as with enals.
- (iii) Conjugated nitroalkenes are highly activated and are thus readily reduced. Whereas chiral centers in the β -position of the

nitroalkanes thus formed are stable, α -analogs are somewhat labile due to the acidity of the α -H.

- (iv) Depending on their degree of activation, α,β -unsaturated carboxylic acids or esters behave as 'borderline'-substrates: whereas simple α,β -unsaturated *mono*-carboxylic acids or -esters are not easily reduced by ene-reductases, they are good substrates for 'enoate-reductases' from anaerobic organisms, which possess an additional (oxygen-sensitive) ferredoxin Fe₄S₄-cofactor (Ferraboschi et al., 1987; Tischer et al., 1979). However, mono-acids or -esters can be activated by an additional electron-withdrawing group, such as a second acid- or ester-group, a halogen or a nitrile (Brenna et al., 2011c; Kitazume and Ishikawa, 1984). Consequently, *di*-carboxylic acids and -esters are well accepted. Cyclic imides, bearing two activating carbonyl groups next to the C=C bond are good substrates in general.
- (v) α,β -Unsaturated nitriles are only slightly activated and also count as 'borderline'-substrates, although complex nitrile-containing molecules have been successfully reduced (Kosjek et al., 2008).

2.3. Enzymes

Enzymes from the 'Old Yellow Enzyme' family are widely distributed in microorganisms and in plants. Some of them occur in well-defined pathways, e.g. in the biosynthesis of jasmonic acid or the metabolism of morphine (Barna et al., 2002; Schaller et al., 2000), others are involved in the detoxification of xenobiotics (Williams et al., 2004), such as trinitrotoluene (TNT, Barna et al., 2001). Over recent years, a great variety of new homologues has been identified and their potential as biocatalysts was investigated. Table 1 gives a summary of ene-reductases used in isolated form in asymmetric bioreduction reactions.

reductase participation in the *syn*-addition of hydrogen to the C=C bond of enones in the cultured cells of *Nicotiana tabacum*. J. Chem. Soc., Perkin Trans. 1. 355–358; Bougioukou, D.J., Stewart, J.D., 2008. Opposite stereochemical courses for enzyme-mediated alkene reductions of an enantiomeric substrate pair. J. Am. Chem. Soc. 130, 7655–7658.

Table 1
Ene-reductases from the 'Old Yellow Enzyme' family.

Enzyme	Organism
Fungi	
Old yellow enzyme 1 (OYE1)	<i>Saccharomyces pastorianus</i> (formerly <i>S. carlsbergensis</i>) (Saito et al., 1991)
Old yellow enzyme 2 and 3 (OYE2 and 3)	<i>Saccharomyces cerevisiae</i> (Karplus et al., 1995)
Old yellow enzyme (OYE)	<i>Candida macedoniensis</i> AKU4588 (Kataoka et al., 2002, 2004)
Estrogen binding protein (EBP1)	<i>Candida albicans</i> (Buckman and Miller, 1998)
<i>Kluyveromyces lactis</i> yellow enzyme 1 (KYE1)	<i>Kluyveromyces lactis</i> (Chaparro-Riggers et al., 2007)
Old yellow enzyme 2.6 (OYE 2.6)	<i>Pichia stipitis</i> CBS 6054 (Padhi et al., 2009)
Bacteria	
YqjM	<i>Bacillus subtilis</i> (Fitzpatrick et al., 2003)
NAD(P)H-dependent 2-cyclohexen-1-one reductase (NCR)	<i>Zymomonas mobilis</i> (Mueller et al., 2007)
Xenobiotic reductase A (XenA)	<i>Pseudomonas putida</i> II-B (Bleher et al., 1999)
Xenobiotic reductase B (XenB)	<i>Pseudomonas fluorescens</i> I-C (Bleher et al., 1999)
Pentaerythritol tetranitrate reductase (PETNr)	<i>Enterobacter cloacae</i> PB2 (French et al., 1996)
TOYE	<i>Thermoanaerobacter pseudoethanolicus</i> E 39 (Adalbjornsson et al., 2010)
SYE1-4	<i>Shewanella oneidensis</i> (Brige et al., 2006)
GkOYE	<i>Geobacillus kaustophilus</i> DSM 7263 (Schittmayer et al., 2010)
Chromate reductase (CrS)	<i>Thermus scotoductus</i> SA-01 (Opperman et al., 2008, 2010)
Morphinone reductase (MR)	<i>Pseudomonas putida</i> M10 (French and Bruce, 1994)
YersER	<i>Yersinia bercovieri</i> (Chaparro-Riggers et al., 2007)
<i>Gluconobacter oxidans</i> ene-reductase	<i>Gluconobacter oxidans</i> DSM 2343 (Richter et al., 2011)
N-ethylmaleimide reductase (NemR)	<i>Escherichia coli</i> (Miura et al., 1997)
Glycerol trinitrate reductase (NerA)	<i>Agrobacterium radiobacter</i> (Snape et al., 1997)
Plants	
12-Oxophytodienoate reductase 1–3 (OPR1-3)	<i>Arabidopsis thaliana</i> (Biesgen and Weiler, 1999; Costa et al., 2000; Schaller and Weiler, 1997)
12-Oxophytodienoate reductase 1–3 (LeOPR1-3)	<i>Solanum lycopersicum</i> (formerly <i>Lycopersicon esculentum</i>) (Strassner et al., 1999, 2002)
Commercially available ERED101-114	Source not available (Kosjek et al., 2008)

2.4. Cofactor regeneration

A major limitation to the broad application of nicotinamide-dependent enzymes for synthetic purpose lies in the prohibitive cost of these natural cofactors, especially the reduced form (~500 €/g NADH and 1400 €/g NADPH, from chemical suppliers). Fortunately, advances in cofactor regeneration techniques now allow the use of catalytic amounts of NAD(P)H and various systems have been exploited with ene-reductases for in situ recycling (Fig. 1) (Faber, 2011; Hall and Bommarius, 2011), while often serving as driving force to overcome thermodynamic equilibrium limitations (Park et al., 2011).

A common strategy for the regeneration of NADH is the formate dehydrogenase (FDH)-catalyzed oxidation of formate to CO₂. FDH has been successfully employed with ene-reductases, although substrate and product depletions were observed with an enal (citronellal), resulting from carbonyl reduction caused by *prim*-ADH impurities in the commercial FDH preparation; likewise, racemisation of α -substituted cycloalkanones was observed (Hall et al., 2008a). Recently, alcohol dehydrogenase ADH-'A' was successfully combined with several ene-reductases, using only 2 equivalents of 2-propanol as H-donor, thereby producing acetone. As above, aldehydes are not suitable substrates due to over-reduction of the CH=O moiety (Tauber et al., 2011). Glucose-6-phosphate dehydrogenase (G6PDH) and glucose dehydrogenase (GDH) are commonly used as cofactor recycling systems for ene-reductases (Hall et al., 2007, 2008b). While G6PDH only accepts NADP⁺, GDH can be employed with both nicotinamide cofactors.

Occasionally, the nature of the substrate had a dramatic influence on the efficiency of the recycling system. For instance, FDH, GDH and G6PDH were inactive in presence of a *cis*-configured α,β -unsaturated dicarboxylic acid (citraconic acid), which acts as strong chelator for divalent metal ions. The addition of metals (e.g. Ca²⁺, Mg²⁺ or Zn²⁺) to the reaction medium proved necessary to overcome deactivation of the recycling enzymes and to make this substrate amenable to bioreduction (Stueckler et al., 2007).

While FDH produces CO₂ and ADH forms highly volatile acetone, GDH and G6PDH furnish gluconolactone/gluconic acid and

6-phosphogluconate respectively, both unstable compounds that hydrolyse spontaneously. This renders all four systems practically irreversible and thereby shifts the equilibrium towards reduction. Phosphite dehydrogenase (PTDH) (Vrtis et al., 2002; Woodyer et al., 2003) has also been applied to the reduction of α,β -unsaturated nitriles, which provides in situ pH-control as phosphate is being produced throughout the reaction (Kosjek et al., 2008).

While all these systems represent coupled-enzyme approaches requiring two proteins, the first example of a coupled-substrate single-enzyme approach applied to ene-reductases was recently published, where advantage was taken of the disproportionation of enones catalyzed by a single ene-reductase. With the enone substrate being reduced to the corresponding saturated ketone, a sacrificial enone co-substrate served as artificial H-donor and was oxidized, thereby rendering the reduced flavin for a subsequent catalytic cycle. 2-Enones and 1,4-diones were particularly good co-substrates as their oxidized forms spontaneously tautomerized to phenol and hydroquinone derivatives, respectively, thus driving the reaction to the desired product side (Stueckler et al., 2010b).

Nonconventional regeneration methods are also being developed (Hollmann et al., 2010). A light-driven system was designed with YqjM, where irradiation with white light in the presence of external free flavin and EDTA allowed the full conversion of 4-ketoisophorone to levodione. The system, however, was plagued by the non-stereoselective background reaction catalyzed by free flavin, leading to reduced product enantiopurity (Taglieber et al., 2008).

3. Applications

3.1. Synthesis of amino acid derivatives

Natural and non-natural amino acids are valuable building blocks and key intermediates for a number of pharmaceuticals, heterocycles or modified peptides (Goodman et al., 2007; Hughes and Moody, 2007; Trabocchi et al., 2005). Ene-reductases have been successfully used for the synthesis of various α - and β -amino acid analogs. In a process developed by Swiderska and Stewart




Fig. 2. Route to β^2 -amino acids.




Fig. 3. Reduction of α,β -dehydroamino acid derivatives by ene-reductases.

(2006), β -nitroacrylates **1a–4a** were stereoselectively reduced by OYE1 to the corresponding β -nitro carboxylic acid esters as the key step in the asymmetric synthesis of optically active β^2 -amino acids (Fig. 2). Since the bioreduction of the C=C bond proceeded chemoselectively, the nitro group was subsequently reduced with Raney-Ni. Ethyl α -alkyl- β -nitroacrylates were reduced with high stereoselectivity ($ee \geq 87\%$) and β^2 -amino acids were isolated as their hydrochloride salts (**1b–4b**) in good overall yield (57–73%). β -Alkyl- β -nitroacrylates (β^3 -amino acid precursors) on the other hand were reduced with low stereoselectivities, most likely due to the α -protonation occurring after product release from the active site.

Recently, α,β -dehydroamino acid derivatives have been identified as novel substrates for members of the OYE family (Fig. 3) (Stueckler et al., 2011). While an α -amino acid precursor having an additional methyl group at C β (methyl 3-methyl-2-acetamidoacrylate) and an α -alanine precursor (methyl 3-acetamidoacrylate) were unreactive, *N*-acyl derivative of alanine (**5a**) and aspartic acid ester (**8a**) were reduced by YqjM to the corresponding (*S*)-enantiomers (**5b**, 41% conv., 97% ee ; **8b**, up to quantitative yield and 99% ee). A switch of stereopreference in the reduction of aspartic acid derivatives **6a–11a** could be induced with OYE3 via substrate engineering by variation of the size of the *N*-acyl protective group. While **6a**, **7a** and **10a** were reduced to the (*S*)-amino acid derivatives (23% to >99% ee), the (*R*)-enantiomers were obtained from **8a**, **9a** and **11a** (61% up to 92% ee). ²H-labelling experiments in D₂O revealed that the opposite stereochemical

outcome by OYE3 was due to a flipped “bottom/top” orientation of the substrate, resulting in an exchange of the activating ester as docking group in the active site. This switch of the activating group opens new perspectives for the asymmetric synthesis of β -amino acids.

3.2. Terpenoids

Terpenoids are one of the largest classes of natural products offering a great variety of biologically active compounds and chiral intermediates. Enantiomers of dihydrocarvone (**12b**) are minor components of essential oils produced by plants and have been used as chiral starting compounds in the synthesis of natural products (e.g. striatenic acid, pechueloic acid) (Aubin et al., 2006; Blay et al., 2007; Harrowven et al., 2005), antimalarial drugs (Dong et al., 2010) and valuable chiral synthons (de Rouville et al., 2009; Krawczyk et al., 2007). In the course of exploring the substrate specificity of PETN reductase (Fryszkowska et al., 2009), (*S*)- and (*S*)-carvone (**12a**) were quantitatively reduced into the diastereomeric products (**12b**) with the same absolute (*R*)-configuration on the newly generated centre at C2 in 95% and 88% diastereomeric excess, respectively (Fig. 4).

Both enantiomers of citronellal (**13b**), a key intermediate in menthol synthesis, have been prepared with excellent ee values (> 95%) starting from (*E/Z*)-citral (**13b**) using various OYEs (Fig. 5) (Bougioukou et al., 2010; Fryszkowska et al., 2009; Hall et al., 2007, 2008a,b; Mueller et al., 2010). While (*S*)-citronellal [(*S*)-**13b**] could be produced quantitatively, (*R*)-citronellal [(*R*)-**13b**] was obtained with 69% conversion. It was observed that the (*E/Z*)-configuration of citral played a crucial role in the stereoselectivity of OYEs 1–3 (Mueller et al., 2007). Whereas whole cells generally led to over-reduction of the product to the corresponding saturated alcohol (Hall et al., 2006; Mueller et al., 2006), isolated OYE-enzymes furnished the aldehyde **13b** as single product.

3.3. Fragrance compounds

α -Methyl dihydrocinnamaldehyde derivatives (**14b** and **15b**) are of commercial importance (Brenna et al., 2003), with **14b** being the olfactory principle of the lily-of-the-valley odor (Enders and Dyker, 1990), marketed under the trade name Lilial™ or Lysmeral™, while **15b**, marketed as Helional™ or Tropional™, is the active ingredient of various perfumes (Enders and Backes, 2004). A convenient enzymatic strategy for the synthesis of **14b** and **15b** was developed (Stueckler et al., 2010a) via bioreduction of α -methyl cinnamaldehydes (**14a** and **15a**) with OYEs. The (*S*)-antipodes were produced with OYE1-3 in an aqueous-organic biphasic system (containing 20% *t*-BuOMe) in >95% ee and quantitative yield (Fig. 6).

3.4. Chiral building blocks

(*6R*)-Levodione (**16b**), obtained by asymmetric bioreduction of 4-ketoisophorone (**16a**), represents an important industrial intermediate for carotenoid synthesis (e.g. zeaxanthin, cryptoxanthin,



Fig. 4. Total asymmetric synthesis of striatenic and pechueloic acid via ene-reductase catalyzed reduction of carvone **12a** producing the key intermediate **12b**.




Fig. 5. Bioreduction of citral (**13a**) to citronellal (**13b**).




Fig. 6. Fragrance production with ene-reductases.

xanthoxin) (Demole and Enggist, 1974). So far, all OYE family members have yielded strictly the (*R*)-enantiomer (up to >99% ee) (Toogood et al., 2010). A one-pot two-step enzymatic cascade was developed leading to (4*R*,6*R*)-actinol (**16c**). The first ene-reduction was catalyzed by OYE2, expressed in *E. coli* and used as cell extract, to furnish (6*R*)-levodione (**16b**) as intermediate. The latter was subsequently reduced at the carbonyl group to actinol (**16c**) with levodione reductase from *Corynebacterium aquaticum* M-13, also expressed in *E. coli*. Glucose dehydrogenase was used for the regeneration of NADH, which allowed the quantitative formation of (4*R*,6*R*)-actinol (**16c**) in 94% ee (Fig. 7) (Wada et al., 2003).

Due to its broad acceptance as a substrate by a large number of OYE homologues, 4-ketoisophorone (**16a**) emerged as a standard test-substance for the characterization of ene-reductases [(OPR1 and OPR3 (Hall et al., 2007, 2008a), YqjM (Hall et al., 2008a), OYE1-3 and NCR (Hall et al., 2008b), PETNr (Fryszkowska et al., 2009; Mueller et al., 2010), NemR, MR and EBP1 (Mueller et al., 2010), *Glucobacter oxidans* ER (Richter et al., 2011), XenA (Chaparro-Riggers et al., 2007; Yanto et al., 2010), TOYE (Adalbjornsson et al., 2010), CrS (Opperman et al., 2010), YersER and KYE1 (Chaparro-Riggers et al., 2007), OYE from *Candida macedoniensis* (Kataoka et al., 2004)], the screening for novel ene-reductase activity in organisms (Goretti et al., 2011; Raimondi et al., 2010) and the development of novel cofactor regeneration systems (Taglieber et al., 2008, 2010; Tauber et al., 2011).

Chiral acyloins (**17b–21b**) are important building blocks in asymmetric synthesis (Adam et al., 1999; Demir et al., 2007; Patel, 2006). They can be converted into nonracemic diols,

epoxides, aminoalcohols, hydroxylamines, and haloketones (Fig. 8). In addition to the classical asymmetric synthesis involving *N*-sulfonyloxaziridines (Davis and Chen, 1992; Davis et al., 1986; Hughes et al., 2005), and several biocatalytic systems (Adam et al., 1999; Demir et al., 2007; Patel, 2006), an additional biocatalytic alternative was recently provided through the asymmetric reduction of α,β -unsaturated alkoxy ketones (Winkler et al., 2010). Stereocomplementary routes to *O*-protected acyloins were developed via substrate engineering through variation of the size of the *O*-protecting group. Both enantiomers of α -alkoxy enones could be obtained in up to >99% ee, while β -analogs were not converted. The *O*-protected acyloins thus obtained can be used in further synthetic steps; particularly allyl- or benzyl-moieties can be easily removed under mild conditions.

Enantiopure lactones are valuable synthetic precursors. For instance, γ -butyrolactone (**22c**) has been utilized as building block in the synthesis of natural products such as milbemycin β_3 , jasplakinolide and amphidinolides (Fig. 9) (Korpak and Pietruszka, 2011). Two of its four possible stereoisomers were recently obtained via an enzymatic two-step one-pot cascade. In the first step, OYE1 was employed for the generation of the first stereocenter, where reduction of the two (*E/Z*)-isomers of starting material **22a** was stereoconvergent and yielded the (*R*)-enantiomer **22b**. In the second step, various alcohol dehydrogenases (ADH) were used for carbonyl reduction leading to the γ -hydroxy ester, followed by spontaneous lactonization to **22c** (Korpak and Pietruszka, 2011). The carbonyl reduction proceeded with enzyme-based stereocontrol, where proper choice of the catalyst allowed both (2*R*,4*S*)-**22c** (with Prelog-type ADH-T from *Thermoanaerobacter* species) and (2*R*,4*R*)-**22c** (with anti-Prelog-type ADH-LK from *Lactobacillus kefir*) in good yields (up to 80%) and perfect stereoselectivity (>99% ee).

(*R*)-3-Hydroxy-2-methylpropanoate (**23b**), commonly denoted as 'Roche-Ester', is a popular chiral building block for the synthesis of vitamins (vitamin E), fragrance compounds (muscone), antibiotics (rapamycin) and natural products (Stueckler et al., 2010c). Prominent routes for its preparation include enzymatic oxidation of prochiral diols (Molinari et al., 2003) or the transition metal-catalyzed asymmetric hydrogenation of acrylate esters using Rh- (Holz et al., 2008; Qiu et al., 2009; Wassenaar




Fig. 7. Ene-reductase catalyzed reduction of 4-ketoisophorone (**16a**) to (*R*)-levodione (**16b**) and (4*R*,6*R*)-actinol (**16c**).




Fig. 8. Production of chiral acyloins via ene-reductases using OYE1-3, YqjM, NerA, OPR1, OPR3, XenA, XenB, EBP1 and NCR.




Fig. 9. A two-step one-pot cascade leading to γ -butyrolactones (**22c**).

et al., 2008) or Ru-catalysts (Pautigny et al., 2008). A biocatalytic equivalent was shown using ene-reductases. The reaction proceeded via strict (*R*)-stereoselective reduction of methyl 2-hydroxymethylacrylate derivatives (>99% *ee* in almost all cases; Fig. 10), with ene-reductases showing overall broad acceptance for this type of compounds (Stueckler et al., 2010c). Substrate engineering via hydroxyl-group protection (allyl-, benzyl- or TBDMS-ethers) enhanced the reaction rate significantly (up to >99% conversion) and hence allowed direct access to protected (*R*)-'Roche-Ester' (**23b**), a convenient intermediate for further synthesis.

Chiral α -halogenated carboxylic acids and esters are useful synthons since they can be transformed into a broad range of derivatives by stereospecific nucleophilic substitution reactions with nitrogen (Righi et al., 2006), oxygen (Hesek et al., 2009; Yang et al., 2001) and sulfur (Narendra et al., 2010; Seki et al., 2000) nucleophiles. Enantiopure α -haloesters in particular are valuable chiral synthons for the synthesis of several therapeutic agents used for the treatment of non-insulin dependent type 2 diabetes mellitus (T2DM) (Brenna et al., 2011c). Brenna and co-workers investigated the bioreduction of various methyl α -halo- β -substituted acrylates using isolated OYE1-3 and baker's yeast (Fig. 11) (Brenna et al., 2011b). OYE3 furnished the corresponding (*S*)-products in good to excellent stereoselectivity (*ee* \geq 88%). The conversion strongly depended on the substitution pattern of the aromatic ring. In general, electron-donating groups on the ring lowered the reaction rate (**31a** and **33a**, conversion

up to 20%), while electron-withdrawing groups increased conversion levels (**28a–30a**, conversion 58–91%) in comparison with the non-substituted derivatives (**27a** and **32a**, conversion 37–38%). The latter can be explained by the varying degree of polarization of the C=C bond. Both chloro- and bromo-substituents at the α -position were accepted by the enzyme. (*S*)- α -Chlorocinnamates **28b** and **30b** were recovered from baker's yeast fermentation and subsequently transformed into non-natural *D*-phenylalanine derivatives (**28c** and **30c**), thus offering a new route to enantiomerically pure non-natural α -amino acid derivatives. A library of α,β -unsaturated α -halo esters bearing various alkyl chains was also tested (**34–37a**, Fig. 11) (Brenna et al., 2011c). Most interestingly, in contrast to the opposite stereopreference observed in baker's yeast-mediated reduction of (*E/Z*)-isomers of α,β -unsaturated α -chloroesters [(Utaka et al., 1989), also confirmed with isolated OYE1-3 acting on methyl 2-chloro-4-methylpent-2-enoate (Brenna et al., 2011a)], both (*E/Z*)-isomers of the α -bromo-analogs were converted to the (*S*)-product (*ee* up to 97%).

Enantiopure nitriles are versatile chiral building blocks due to their chemical reactivity, allowing further transformation into numerous functional groups (e.g. carboxylic acids, amines or aldehydes). For instance, nitrile **42b** contains a spiro piperidine backbone and is relevant for pharmaceutical research (Fig. 12) (Jia et al., 2007; Limanto et al., 2008; Lu et al., 2007). In a study with commercially available ene-reductases, the C=C bond of a series of α,β -unsaturated nitriles were reduced in high yields and stereoselectivities (up to 99% *ee*, Fig. 12) (Kosjek et al., 2008). While all




Fig. 10. Roche ester production via ene-reductases using OYE1-3, YqjM, NCR, NerA, OPR1, OPR3 and XenA.




Fig. 11. Ene-reductase-catalyzed reduction of α -halo-esters and further transformation into chiral products.




Fig. 12. Ene-reductase-catalyzed production of enantiopure nitriles.

enzymes showed (*R*)-selectivity for substrates **38a–41a**, the absolute configuration of **42b** was not assigned.

4. Concluding remarks

Ene-reductases from the ‘Old Yellow Enzyme’ family of flavo-proteins have attracted increasing interest from synthetic chemists over the last years due to their exquisite chemo-, regio-, and stereoselectivities. Their use in the reduction of various α,β -unsaturated compounds has been successfully developed to allow the synthesis of enantiopure molecules with high synthetic value and industrial potential. The implementation of a nicotinamide cofactor regeneration renders the process cost-effective and highly competitive, while the availability of numerous OYE-homologues with stereocomplementary activities provides access to both enantiomeric forms of many synthons. Substrate engineering also revealed to be a powerful tool to control the stereoselectivity of the reaction.

With the advances of molecular biology tools, it can be expected that protein engineering applied to ene-reductases will further broaden their applicability. Structure-guided approaches combined with directed evolution have been recently used to enhance their catalytic properties, where few mutations were sufficient to reverse the stereopreference and/or increase reaction rates (Bougioukou et al., 2009, 2010; Hall and Bommarius, 2011). The remaining challenges to promote ene-reductases for large-scale applications are the improvement of enzyme stability under operational conditions – TTNs are still limited to 10^3 – 10^4 (Yanto et al., 2010) – and the creation of successful ‘designer bugs’, where co-expression of ene-reductases and a suitable cofactor regeneration system will definitely establish these biocatalysts as robust and versatile synthetic tools for large-scale applications.

Acknowledgements

This study was performed in cooperation within the Austrian Centre of Industrial Biotechnology (ACIB, funded through the FFG-COMET-Program) and project P22722 of the FWF and support by the FWF, BMWFJ, BMVIT, SFG, Standortagentur Tirol, ZIT and BASF SE (Ludwigshafen) is gratefully acknowledged.

References

- Adalbjornsson, B.V., Toogood, H.S., Fryszkowska, A., Pudney, C.R., Jowitt, T.A., Leys, D., Scrutton, N.S., 2010. Biocatalysis with thermostable enzymes: structure and properties of a thermophilic ‘ene’-reductase related to old yellow enzyme. *ChemBioChem* 11, 197–207.
- Adam, W., Lazarus, M., Saha-Möller, C.R., Schreier, P., 1999. Biocatalytic synthesis of optically active α -oxyfunctionalized carbonyl compounds. *Acc. Chem. Res.* 32, 837–845.
- Aubin, Y., Audran, G., Monti, H., 2006. Improved enantioselective synthesis of natural striatenic acid and its methyl ester. *Tetrahedron Lett.* 47, 3669–3671.
- Barna, T., Messiha, H.L., Petosa, C., Scrutton, N.S., Moody, P.C.E., Bruce, N.C., 2002. Crystal structure of bacterial morphinone reductase and properties of the C191A mutant enzyme. *J. Biol. Chem.* 277, 30976–30983.
- Barna, T.M., Khan, H., Bruce, N.C., Barsukov, I., Moody, P.C.E., Scrutton, N.S., 2001. Crystal structure of pentaerythritol tetranitrate reductase: flipped binding geometries for steroid substrates in different redox states of the enzyme. *J. Mol. Biol.* 310, 433–447.
- Biesgen, C., Weiler, E.W., 1999. Structure and regulation of OPR1 and OPR2, two closely related genes encoding 12-oxophytodienoic acid-10,11-reductases from *Arabidopsis thaliana*. *Planta* 208, 155–165.
- Blay, G., Garcia, B., Molina, E., Pedro, J.R., 2007. Synthesis of (+)-pechueloic acid and (+)-aciphylle. Revision of the structure of (+)-aciphylle. *Tetrahedron* 63, 9621–9626.
- Blehert, D.S., Chambliss, G.H., Fox, B.G., 1999. Cloning and sequence analysis of two *Pseudomonas* flavoprotein xenobiotic reductases. *J. Bacteriol.* 181, 6254–6263.
- Bougioukou, D.J., Kille, S., Taglieber, A., Reetz, M.T., 2009. Directed evolution of an enantioselective enoate-reductase: testing the utility of iterative saturation mutagenesis. *Adv. Synth. Catal.* 351, 3287–3305.

- Bougioukou, D.J., Walton, A.Z., Stewart, J.D., 2010. Towards preparative-scale, biocatalytic alkene reductions. *Chem. Commun. (Cambridge)* 46, 8558–8560.
- Brenna, E., Fronza, G., Fuganti, C., Monti, D., Parmeggiani, F., 2011a. Enantioselective C=C bond reduction of unsaturated α -chloro esters by old yellow enzymes. *J. Mol. Catal. B: Enzym.* 73, 17–21.
- Brenna, E., Fuganti, C., Serra, S., 2003. Enantioselective perception of chiral odorants. *Tetrahedron Asymmetry* 14, 1–42.
- Brenna, E., Gatti, F.G., Manfredi, A., Monti, D., Parmeggiani, F., 2011b. Biocatalyzed enantioselective reduction of activated C=C bonds: synthesis of enantiomerically enriched α -halo- β -arylpropionic acids. *Eur. J. Org. Chem.* 2011, 4015–4022.
- Brenna, E., Gatti, F.G., Manfredi, A., Monti, D., Parmeggiani, F., 2011c. Enoate reductase-mediated preparation of (S)-methyl 2-bromobutanoate, a useful key intermediate for the synthesis of chiral active pharmaceutical ingredients. *Org. Process Res. Dev.* 16, 262–268.
- Brige, A., Van den Hemel, D., Carpentier, W., De Smet, L., Van Beeumen, J.J., 2006. Comparative characterization and expression analysis of the four Old Yellow Enzyme homologues from *Shewanella oneidensis* indicate differences in physiological function. *Biochem. J.* 394, 335–344.
- Buckman, J., Miller, S.M., 1998. Binding and reactivity of *Candida albicans* estrogen binding protein with steroid and other substrates. *Biochemistry (Moscow)* 37, 14326–14336.
- Chaparro-Riggers, J.F., Rogers, T.A., Vazquez-Figueroa, E., Polizzi, K.M., Bommarius, A.S., 2007. Comparison of three enoate reductases and their potential use for biotransformations. *Adv. Synth. Catal.* 349, 1521–1531.
- Costa, C.L., Arruda, P., Benedetti, C.E., 2000. An *Arabidopsis* gene induced by wounding functionally homologous to flavoprotein oxidoreductases. *Plant Mol. Biol.* 44, 61–71.
- Davis, F.A., Chen, B.C., 1992. Asymmetric hydroxylation of enolates with N-sulfonyloxaziridines. *Chem. Rev.* 92, 919–934.
- Davis, F.A., Haque, M.S., Ulatowski, T.G., Towson, J.C., 1986. Asymmetric oxidation of ester and amide enolates using new (camphorylsulfonyl)oxaziridines. *J. Org. Chem.* 51, 2402–2404.
- de Rouville, H.P.J., Vives, G., Tur, E., Rapenne, G., Crassous, J., 2009. Synthesis and analytical resolution of chiral pyrazoles derived from (5R)-dihydrocarvone. *New J. Chem.* 33, 293–299.
- Demir, A.S., Ayhan, P., Sopaci, S.B., 2007. Thiamine pyrophosphate dependent enzyme catalyzed reactions: stereoselective C–C bond formations in water. *Clean: Soil Air Water* 35, 406–412.
- Demole, E., Enggist, P., 1974. Novel synthesis of 3,5,5-trimethyl-4-(2-butenylidene)-cyclohex-2-en-1-one, a major constituent of burley tobacco flavour. *Helv. Chim. Acta* 57, 2087–2091.
- Dong, Y., McCullough, K.J., Wittlin, S., Chollet, J., Vennerstrom, J.L., 2010. The structure and antimicrobial activity of dispiro-1,2,4,5-tetraoxanes derived from (+)-dihydrocarvone. *Bioorg. Med. Chem. Lett.* 20, 6359–6361.
- Enders, D., Backes, M., 2004. First asymmetric synthesis of both enantiomers of Tropinal® and their olfactory evaluation. *Tetrahedron Asymmetry* 15, 1813–1817.
- Enders, D., Dyker, H., 1990. Synthesis and properties of the enantiomers of the two artificial fragrances liliol and methylundecanal. *Liebigs Ann. Chem.* 1990, 1107–1110.
- Faber, K., 2011. *Biotransformations in Organic Chemistry*, 6th ed. Springer, Berlin, Heidelberg.
- Ferraboschi, P., Grisenti, P., Casati, R., Fiechi, A., Santaniello, E., 1987. Biohydrogenation of unsaturated-compounds by *Saccharomyces cerevisiae*. 1. Stereochemical aspects of the reaction and preparation of useful bifunctional chiral synthons. *J. Chem. Soc., Perkin Trans. 1*, 1743–1748.
- Fitzpatrick, T.B., Amrhein, N., Macheroux, P., 2003. Characterization of YqjM, an old yellow enzyme homolog from *Bacillus subtilis* involved in the oxidative stress response. *J. Biol. Chem.* 278, 19891–19897.
- French, C.E., Bruce, N.C., 1994. Purification and characterization of morphinone reductase from *Pseudomonas putida* M10. *Biochem. J.* 301, 97–103.
- French, C.E., Nicklin, S., Bruce, N.C., 1996. Sequence and properties of pentaerythritol tetranitrate reductase from *Enterobacter cloacae* PB2. *J. Bacteriol.* 178, 6623–6627.
- Fryszkowska, A., Toogood, H., Sakuma, M., Gardiner, J.M., Stephens, G.M., Scrutton, N.S., 2009. Asymmetric reduction of activated alkenes by pentaerythritol tetranitrate reductase: specificity and control of stereochemical outcome by reaction optimisation. *Adv. Synth. Catal.* 351, 2976–2990.
- Goodman, C.M., Choi, S., Shandler, S., DeGrado, W.F., 2007. Foldamers as versatile frameworks for the design and evolution of function. *Nat. Chem. Biol.* 3, 252–262.
- Goretti, M., Ponzoni, C., Caselli, E., Marchegiani, E., Cramarossa, M.R., Turchetti, B., Forti, L., Buzzini, P., 2011. Bioreduction of α,β -unsaturated ketones and aldehydes by non-conventional yeast (NCY) whole-cells. *Bioresour. Technol.* 102, 3993–3998.
- Hall, M., Bommarius, A.S., 2011. Enantioenriched compounds via enzyme-catalyzed redox reactions. *Chem. Rev.* 111, 4088–4110.
- Hall, M., Hauer, B., Stuermer, R., Kroutil, W., Faber, K., 2006. Asymmetric whole-cell bioreduction of an alpha,beta-unsaturated aldehyde (citral): competing primary alcohol dehydrogenase and C=C lyase activities. *Tetrahedron: asymmetry* 17, 3058–3062.
- Hall, M., Stueckler, C., Ehammer, H., Pointner, E., Oberdorfer, G., Gruber, K., Hauer, B., Stuermer, R., Kroutil, W., Macheroux, P., Faber, K., 2008a. Asymmetric bioreduction of C=C bonds using enoate reductases OPR1, OPR3 and YqjM: enzyme-based stereocontrol. *Adv. Synth. Catal.* 350, 411–418.
- Hall, M., Stueckler, C., Hauer, B., Stuermer, R., Friedrich, T., Breuer, M., Kroutil, W., Faber, K., 2008b. Asymmetric bioreduction of activated C=C bonds using *Zymomonas mobilis* NCR enoate reductase and old yellow enzymes OYE 1–3 from yeasts. *Eur. J. Org. Chem.* 9, 1511–1516.
- Hall, M., Stueckler, C., Kroutil, W., Macheroux, P., Faber, K., 2007. Asymmetric bioreduction of activated alkenes using cloned 12-oxophytodienoate reductase isoenzymes OPR-1 and OPR-3 from *Lycopersicon esculentum* (Tomato): a striking change of stereoselectivity. *Angew. Chem. Int. Ed.* 46, 3934–3937.
- Hall, M., Yanto, Y., Bommarius, A.S., 2010. Enzymes, Enoate Reductases 'Old Yellow Enzyme'. John Wiley & Sons, Hoboken.
- Harrowven, D.C., Pascoe, D.D., Demurtas, D., Bourne, H.O., 2005. Total synthesis of (–)-colombianin A and (–)-elisapterosin B. *Angew. Chem. Int. Ed.* 44, 1221–1222.
- Hesek, D., Lee, M., Zhang, W., Noll, B.C., Mobashery, S., 2009. Total synthesis of N-acetylglucosamine-1,6-anhydro-N-acetylmuramylpentapeptide and evaluation of its turnover by AmpD from *Escherichia coli*. *J. Am. Chem. Soc.* 131, 5187–5193.
- Hollmann, F., Arends, I.W.C.E., Buehler, K., 2010. Biocatalytic redox reactions for organic synthesis: nonconventional regeneration methods. *ChemCatChem* 2, 762–782.
- Holz, J., Schäffner, B., Zayas, O., Spannenberg, A., Börner, A., 2008. Synthesis of chiral 2-hydroxy-1-methylpropanoates by rhodium-catalyzed stereoselective hydrogenation of α -(hydroxymethyl)-acrylate derivatives. *Adv. Synth. Catal.* 350, 2533–2543.
- Hughes, C.C., Miller, A.K., Trauner, D., 2005. An electrochemical approach to the guanacastepenes. *Org. Lett.* 7, 3425–3428.
- Hughes, R.A., Moody, C.J., 2007. From amino acids to heteroaromatics—thiopeptide antibiotics, nature's heterocyclic peptides. *Angew. Chem. Int. Ed.* 46, 7930–7954.
- Jia, L., Zou, J., So, S.-S., Sun, H., 2007. Automated pharmacophore query optimization with genetic algorithms. A case study using the MC4R System. *J. Chem. Inf. Model.* 47, 1545–1552.
- Karplus, P.A., Fox, K.M., Massey, V., 1995. Flavoprotein structure and mechanism. 8. Structure–function relations for old yellow enzyme. *FASEB J.* 9, 1518–1526.
- Kataoka, M., Kotaka, A., Hasegawa, A., Wada, M., Yoshizumi, A., Nakamori, S., Shimizu, S., 2002. Old yellow enzyme from *Candida macedoniensis* catalyzes the stereospecific reduction of the C=C bond of ketoisophorone. *Biosci. Biotechnol. Biochem.* 66, 2651–2657.
- Kataoka, M., Kotaka, A., Thiwthong, R., Wada, M., Nakamori, S., Shimizu, S., 2004. Cloning and overexpression of the old yellow enzyme gene of *Candida macedoniensis*, and its application to the production of a chiral compound. *J. Biotechnol.* 114, 1–9.
- Kitazume, T., Ishikawa, N., 1984. Diastereoselective reduction of perfluoroalkylated alpha,beta-unsaturated ketones with bakers-yeast. *Chem. Lett.*, 587–590.
- Knowles, W.S., 2002. Asymmetric hydrogenations (Nobel lecture). *Angew. Chem. Int. Ed.* 41, 1999–2007.
- Kohli, R.M., Massey, V., 1998. The oxidative half-reaction of old yellow enzyme. The role of tyrosine 196. *J. Biol. Chem.* 273, 32763–32770.
- Korpak, M., Pietruszka, J., 2011. Chemoenzymatic one-pot synthesis of γ -butyrolactones. *Adv. Synth. Catal.* 353, 1420–1424.
- Kosjek, B., Fleitz, F.J., Dormer, P.G., Kuethe, J.T., Devine, P.N., 2008. Asymmetric bioreduction of alpha,beta-unsaturated nitriles and ketones. *Tetrahedron Asymmetry* 19, 1403–1406.
- Krawczyk, H., Sliwinski, M., Kedzia, J., Wojciechowski, J., Wolf, W.M., 2007. Asymmetric synthesis of enantiomerically pure 7-isopropenyl-4a-methyl-3-methyleneoctahydrochromen-2-ones. *Tetrahedron Asymmetry* 18, 2712–2718.
- Limanto, J., Shultz, C.S., Dorner, B., Desmond, R.A., Devine, P.N., Kraska, S.W., 2008. Synthesis of a tertiary carbinamide via a novel Rh-catalyzed asymmetric hydrogenation. *J. Org. Chem.* 73, 1639–1642.
- List, B., Yang, J.W., 2006. The organic approach to asymmetric catalysis. *Science* 313, 1584–1586.
- Lu, Z., Tata, J.R., Cheng, K., Wei, L., Chan, W.W.S., Butler, B., Schleim, K.D., Jacks, T.M., Hickey, G., Patchett, A.A., 2007. Highly potent growth hormone secretagogues. *Bioorg. Med. Chem. Lett.* 17, 3657–3659.
- Miura, K., Tomioka, Y., Suzuki, H., Yonezawa, M., Hishinuma, T., Mizugaki, M., 1997. Molecular cloning of the nemA gene encoding N-ethylmaleimide reductase from *Escherichia coli*. *Biol. Pharm. Bull.* 20, 110–112.
- Molinari, F., Gandolfi, R., Villa, R., Urban, E., Kiener, A., 2003. Enantioselective oxidation of prochiral 2-methyl-1,3-propandiol by *Acetobacter pasteurianus*. *Tetrahedron Asymmetry* 14, 2041–2043.
- Mueller, A., Hauer, B., Rosche, B., 2006. Enzymatic reduction of the [alpha], [beta]-unsaturated carbon bond in citral. *J. Mol. Catal. B: Enzym.* 38, 126–130.
- Mueller, A., Hauer, B., Rosche, B., 2007. Asymmetric alkene reduction by yeast old yellow enzymes and by a novel *Zymomonas mobilis* reductase. *Biotechnol. Bioeng.* 98, 22–29.
- Mueller, N.J., Stueckler, C., Hauer, B., Baudendistel, N., Housden, H., Bruce, N.C., Faber, K., 2010. The substrate spectra of pentaerythritol tetranitrate reductase, morphinone reductase, N-ethylmaleimide reductase and estrogen-binding protein in the asymmetric bioreduction of activated alkenes. *Adv. Synth. Catal.* 352, 387–394.
- Narendra, N., Lalithamba, H.S., Sureshbabu, V.V., 2010. An efficient one-pot access to trithiocarbonate-tethered peptidomimetics. *Tetrahedron Lett.* 51, 6169–6173.
- Noyori, R., 2002. Asymmetric catalysis: science and opportunities (Nobel lecture). *Angew. Chem. Int. Ed.* 41, 2008–2022.
- Opperman, D.J., Piater, L.A., van Heerden, E., 2008. A novel chromate reductase from *Thermus scotoductus* SA-01 related to old yellow enzyme. *J. Bacteriol.* 190, 3076–3082.
- Opperman, D.J., Sewell, B.T., Litthauer, D., Isupov, M.N., Littlechild, J.A., van Heerden, E., 2010. Crystal structure of a thermostable Old Yellow Enzyme from *Thermus scotoductus* SA-01. *Biochem. Biophys. Res. Commun.* 393, 426–431.

- Padhi, S.K., Bougioukou, D.J., Stewart, J.D., 2009. Site-saturation mutagenesis of tryptophan 116 of *Saccharomyces pastorianus* Old Yellow Enzyme uncovers stereocomplementary Variants. *J. Am. Chem. Soc.* 131, 3271–3280.
- Park, J.T., Hirano, J.I., Thangavel, V., Riebel, B.R., Bommarius, A.S., 2011. NAD(P)H oxidase V from *Lactobacillus plantarum* (NoxV) displays enhanced operational stability even in absence of reducing agents. *J. Mol. Catal. B: Enzym.* 71, 159–165.
- Patel, R.N., 2006. Biocatalysis: synthesis of chiral intermediates for pharmaceuticals. *Curr. Org. Chem.* 10, 1289–1321.
- Pautigny, C., Jeulin, S., Ayad, T., Zhang, Z., Genêt, J.-P., Ratovelomanana-Vidal, V., 2008. Convenient general asymmetric synthesis of roche ester derivatives through catalytic asymmetric hydrogenation: steric and electronic effects of ligands. *Adv. Synth. Catal.* 350, 2525–2532.
- Qiu, M., Wang, D.-Y., Hu, X.-P., Huang, J.-D., Yu, S.-B., Deng, J., Duan, Z.-C., Zheng, Z., 2009. Asymmetric synthesis of chiral Roche ester and its derivatives via Rh-catalyzed enantioselective hydrogenation with chiral phosphine-phosphoramidite ligands. *Tetrahedron Asymmetry* 20, 210–213.
- Raimondi, S., Roncaglia, L., Amaretti, A., Leonardi, A., Buzzini, P., Forti, L., Rossi, M., 2010. Rapid method for screening enoate reductase activity in yeasts. *J. Microbiol. Methods* 83, 106–110.
- Richter, N., Groeger, H., Hummel, W., 2011. Asymmetric reduction of activated alkenes using an enoate reductase from *Gluconobacter oxydans*. *Appl. Microbiol. Biotechnol.* 89, 79–89.
- Righi, G., Ciambrone, S., D'Achille, C., Leonelli, A., Bonini, C., 2006. Highly efficient stereoselective synthesis of d-erythro-sphingosine and d-lyxo-phytosphingosine. *Tetrahedron* 62, 11821–11826.
- Saito, K., Thiele, D.J., Davio, M., Lockridge, O., Massey, V., 1991. The cloning and expression of a gene encoding Old Yellow Enzyme from *Saccharomyces carlsbergensis*. *J. Biol. Chem.* 266, 20720–20724.
- Schaller, F., Biesgen, C., Mussig, C., Altmann, T., Weiler, E.W., 2000. 12-Oxophytodienoate reductase 3 (OPR3) is the isoenzyme involved in jasmonate biosynthesis. *Planta* 210, 979–984.
- Schaller, F., Weiler, E.W., 1997. Molecular cloning and characterization of 12-oxophytodienoate reductase, an enzyme of the octadecanoid signaling pathway from *Arabidopsis thaliana*. *J. Biol. Chem.* 272, 28066–28072.
- Schittmayer, M., Glieder, A., Uhl, M.K., Winkler, A., Zach, S., Schrittwieser, J.H., Kroutil, W., Macheroux, P., Gruber, K., Kambourakis, S., Rozzell, J.D., Winkler, M., 2010. Old Yellow Enzyme-catalyzed dehydrogenation of saturated ketones. *Adv. Synth. Catal.* 353, 268–274.
- Seki, M., Yamanaka, T., Kondo, K., 2000. Practical synthesis of (R)-4-mercaptopyrrolidine-2-thione from l-aspartic acid. Preparation of a novel orally active 1-β-methylcarbapenem TA-949. *J. Org. Chem.* 65, 517–522.
- Snape, J.R., Walkley, N.A., Morby, A.P., Nicklin, S., White, G.F., 1997. Purification, properties, and sequence of glycerol trinitrate reductase from *Agrobacterium radiobacter*. *J. Bacteriol.* 179, 7796–7802.
- Strassner, J., Furholz, A., Macheroux, P., Amrhein, N., Schaller, A., 1999. A homolog of old yellow enzyme in tomato – spectral properties and substrate specificity of the recombinant protein. *J. Biol. Chem.* 274, 35067–35073.
- Strassner, J., Schaller, F., Frick, U.B., Howe, G.A., Weiler, E.W., Amrhein, N., Schaller, A., Macheroux, P., 2002. Characterization and cDNA-microarray expression analysis of 12-oxophytodienoate reductases reveals differential roles for octadecanoid biosynthesis in the local versus the systemic wound response. *Plant J.* 32, 585–601.
- Stueckler, C., Hall, M., Ehammer, H., Pointner, E., Kroutil, W., Macheroux, P., Faber, K., 2007. Stereocomplementary bioreduction of alpha,beta-unsaturated dicarboxylic acids and dimethyl esters using enoate reductases: Enzyme- and substrate-based stereocontrol. *Org. Lett.* 9, 5409–5411.
- Stueckler, C., Mueller, N.J., Winkler, C.K., Glueck, S.M., Gruber, K., Steinkellner, G., Faber, K., 2010a. Bioreduction of alpha-methylcinnamaldehyde derivatives: chemo-enzymatic asymmetric synthesis of Lilial (TM) and Helional (TM). *Dalton Trans.* 39, 8472–8476.
- Stueckler, C., Reiter, T.C., Baudendistel, N., Faber, K., 2010b. Nicotinamide-independent asymmetric bioreduction of C=C-bonds via disproportionation of enones catalyzed by enoate reductases. *Tetrahedron* 66, 663–667.
- Stueckler, C., Winkler, C.K., Bonnekesel, M., Faber, K., 2010c. Asymmetric synthesis of (R)-3-hydroxy-2-methylpropanoate ('Roche Ester') and derivatives via biocatalytic C=C-bond reduction. *Adv. Synth. Catal.* 352, 2663–2666.
- Stueckler, C., Winkler, C.K., Hall, M., Hauer, B., Bonnekesel, M., Zangger, K., Faber, K., 2011. Stereo-controlled asymmetric bioreduction of alpha,beta-dehydroamino acid derivatives. *Adv. Synth. Catal.* 353, 1169–1173.
- Stuermer, R., Hauer, B., Hall, M., Faber, K., 2007. Asymmetric bioreduction of activated C=C bonds using enoate reductases from the old yellow enzyme family. *Curr. Opin. Chem. Biol.* 11, 203–213.
- Swiderska, M.A., Stewart, J.D., 2006. Asymmetric bioreductions of beta-nitro acrylates as a route to chiral beta(2)-amino acids. *Org. Lett.* 8, 6131–6133.
- Taglieber, A., Schulz, F., Hollmann, F., Rusek, M., Reetz, M.T., 2008. Light-driven biocatalytic oxidation and reduction reactions: scope and limitations. *ChemBioChem* 9, 565–572.
- Taglieber, A., Schulz, F., Hollmann, F., Rusek, M., Reetz, M.T., 2010. Light-driven Stereoselective Biocatalytic Oxidations and Reductions. John Wiley & Sons Ltd, pp. 299–305.
- Tauber, K., Hall, M., Kroutil, W., Fabian, W.M.F., Faber, K., Glueck, S.M., 2011. A highly efficient ADH-coupled NADH-recycling system for the asymmetric bioreduction of carbon-carbon double bonds using enoate reductases. *Biotechnol. Bioeng.* 108, 1462–1467.
- Tischer, W., Bader, J., Simon, H., 1979. Purification and some properties of a hitherto-unknown enzyme reducing the carbon-carbon double-bond of alpha,beta-unsaturated carbonyl anions. *Eur. J. Biochem.* 97, 103–112.
- Toogood, H.S., Gardiner, J.M., Scrutton, N.S., 2010. Biocatalytic reductions and chemical versatility of the old yellow enzyme family of flavoprotein oxidoreductases. *ChemCatChem* 2, 892–914.
- Trabocchi, A., Guarna, F., Guarna, A., 2005. γ- and δ-Amino acids: synthetic strategies and relevant applications. *Curr. Org. Chem.* 9, 1127–1153.
- Utaka, M., Konishi, S., Mizuoka, A., Ohkubo, T., Sakai, T., Tsuboi, S., Takeda, A., 1989. Asymmetric reduction of the prochiral carbon carbon double-bond of methyl 2-chloro-2-alkenoates by use of fermenting bakers-yeast. *J. Org. Chem.* 54, 4989–4992.
- Vrtis, J.M., White, A.K., Metcalf, W.W., van der Donk, W.A., 2002. Phosphite dehydrogenase: a versatile cofactor-regeneration enzyme. *Angew. Chem. Int. Ed.* 41, 3257–3259.
- Wada, M., Yoshizumi, A., Noda, Y., Kataoka, M., Shimizu, S., Takagi, H., Nakamori, S., 2003. Production of a doubly chiral compound, (4R,6R)-4-hydroxy-2,2,6-trimethylcyclohexanone, by two-step enzymatic asymmetric reduction. *Appl. Environ. Microbiol.* 69, 933–937.
- Wassenaar, J., Kuil, M., Reek, J.N.H., 2008. Asymmetric synthesis of the Roche ester and its derivatives by rhodium-INDOLPHOS-catalyzed hydrogenation. *Adv. Synth. Catal.* 350, 1610–1614.
- Williams, R.E., Rathbone, D.A., Scrutton, N.S., Bruce, N.C., 2004. Biotransformation of explosives by the old yellow enzyme family of flavoproteins. *Appl. Environ. Microbiol.* 70, 3566–3574.
- Winkler, C.K., Stueckler, C., Mueller, N.J., Pressnitz, D., Faber, K., 2010. Asymmetric synthesis of O-protected acylolins using enoate reductases: stereochemical control through protecting group modification. *Eur. J. Org. Chem.* 33, 6354–6358.
- Woodyer, R., van der Donk, W.A., Zhao, H.M., 2003. Relaxing the nicotinamide cofactor specificity of phosphite dehydrogenase by rational design. *Biochemistry (Moscow)* 42, 11604–11614.
- Yang, D., Li, B., Ng, F.F., Yan, Y.L., Qu, J., Wu, Y.D., 2001. Synthesis and characterization of chiral N=O turns induced by alpha-aminoxy acids. *J. Org. Chem.* 66, 7303–7312.
- Yang, J.W., Fonseca, M.T.H., Vignola, N., List, B., 2005. Metal-free, organocatalytic asymmetric transfer hydrogenation of alpha,beta-unsaturated aldehydes. *Angew. Chem. Int. Ed.* 44, 108–110.
- Yanto, Y., Winkler, C.K., Lohr, S., Hall, M., Faber, K., Bommarius, A.S., 2011. Asymmetric bioreduction of alkenes using ene-reductases YersER and KYE1 and effects of organic solvents. *Org. Lett.* 13, 2540–2543.
- Yanto, Y., Yu, H.H., Hall, M., Bommarius, A.S., 2010. Characterization of xenobiotic reductase A (XenA): study of active site residues, substrate spectrum and stability. *Chem. Commun.* 46, 8809–8811.